

Ref. No: 1714
Date: 2nd May 2025
Subject: Biologics in Dermatology

REQUEST

Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Apremilast
- Bimekizumab
- Brodalumab
- Certolizumab
- Deucravacitinib
- Dimethyl fumarate
- Etanercept - Enbrel
- Etanercept Biosimilar
- Guselkumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Ixekizumab
- Risankizumab
- Secukinumab
- Tildrakizumab
- Ustekinumab - Stelara
- Ustekinumab Biosimilar
- Omalizumab
- Spesolimab

Q2. How many patients were treated in the last 3 months by the Dermatology department for HS (Hidradenitis Suppurativa) ONLY with the following:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Bimekizumab
- Certolizumab
- Infliximab - Remicade

- **Infliximab Biosimilar**
- **Secukinumab**
- **Ustekinumab - Stelara**
- **Ustekinumab Biosimilar**

RESPONSE

MWL Response

1.

- **Adalimumab – Humira - 13**
- **Adalimumab Biosimilar - 122**
- **Apremilast - 71**
- **Bimekizumab - 0**
- **Brodalumab - 0**
- **Certolizumab - 3**
- **Deucravacitinib - 0**
- **Dimethyl fumarate - 11**
- **Etanercept – Enbrel - 0**
- **Etanercept Biosimilar - 1**
- **Guselkumab - 37**
- **Infliximab – Remicade - 0**
- **Infliximab Biosimilar - 2**
- **Ixekizumab - 9**
- **Risankizumab - 31**
- **Secukinumab - 15**
- **Tildrakizumab - 0**
- **Ustekinumab – Stelara - 8**
- **Ustekinumab Biosimilar - 26**
- **Omalizumab - 25**
- **Spesolimab - 0**

2. Unable to answer as we don't hold information on specific indications.